Research Paper Volume 13, Issue 1 pp 437—449

Accumulation of LOX-1+ PMN-MDSCs in nasopharyngeal carcinoma survivors with chronic hepatitis B might permit immune tolerance to epstein–barr virus and relate to tumor recurrence

LOX-1+ PMN-MDSCs may permit EBV replication in NPC survivors with CHB. (A) LOX-1+ PMN-MDSC levels of NPC survivors of different genders; (B) Linear regression of LOX-1+ PMN-MDSC level with age; (C) LOX-1+ PMN-MDSC level of survivors with positive or negative serum HBV DNA results; (D) LOX-1+ PMN-MDSC level of survivors with different stages of NPC; (E) LOX-1+ PMN-MDSC level of survivors with different NPC pathological subtypes; (F) LOX-1+ PMN-MDSC level of survivors with positive or negative serum EBV DNA; (G) CD8+ T cell responses against the major antigenic EBV proteins, LMP2 and EBNA1, was demonstrated by changes in IFN-γ concentration. Abbreviations: PMN-MDSC, polymorphonuclear myeloid-derived suppressor cell; EBV, Epstein-Barr virus; NPC, nasopharyngeal carcinoma; CHB, chronic hepatitis B; ALT, alanine aminotransferase; KSCC, keratinizing squamous cell carcinoma; NKC, non-keratinizing carcinoma; IFN, interferon.

Figure 5. LOX-1+ PMN-MDSCs may permit EBV replication in NPC survivors with CHB. (A) LOX-1+ PMN-MDSC levels of NPC survivors of different genders; (B) Linear regression of LOX-1+ PMN-MDSC level with age; (C) LOX-1+ PMN-MDSC level of survivors with positive or negative serum HBV DNA results; (D) LOX-1+ PMN-MDSC level of survivors with different stages of NPC; (E) LOX-1+ PMN-MDSC level of survivors with different NPC pathological subtypes; (F) LOX-1+ PMN-MDSC level of survivors with positive or negative serum EBV DNA; (G) CD8+ T cell responses against the major antigenic EBV proteins, LMP2 and EBNA1, was demonstrated by changes in IFN-γ concentration. Abbreviations: PMN-MDSC, polymorphonuclear myeloid-derived suppressor cell; EBV, Epstein-Barr virus; NPC, nasopharyngeal carcinoma; CHB, chronic hepatitis B; ALT, alanine aminotransferase; KSCC, keratinizing squamous cell carcinoma; NKC, non-keratinizing carcinoma; IFN, interferon.